{"id":4898,"date":"2025-08-09T11:00:11","date_gmt":"2025-08-09T17:00:11","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=4898"},"modified":"2025-09-03T22:30:20","modified_gmt":"2025-09-04T04:30:20","slug":"journal-business-vs-editorial-oversight","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/08\/09\/4898\/journal-business-vs-editorial-oversight\/","title":{"rendered":"JOURNAL BUSINESS vs EDITORIAL OVERSIGHT"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

New medical and science journals pop up in our mailbox on a biweekly basis.  Offers to join as Editor, solicitation for articles based on past publications, invitations for subject reviews come as unsolicited emails.  Medical publication houses, old and new, are expanding, adding more and more subspecialties to their established list of publications.  Nature, Science and Lancet have all expanded under the original brand name.  Their business model promises authors fast reviews and streamlined acceptance processes.  This proliferation of journals virtually guarantees publication somewhere and makes acceptance less competitive.  Most journals use a similar business model; most require that authors pay for manuscripts, then charge inordinate amounts of money to non-subscribers for a single article.<\/p>\n\n\n\n

Given this proliferation, it is no surprise that libraries can only afford and subscribe to a core set of journals to stay within budget. [1]<\/a>,[2]<\/a><\/p>\n\n\n\n

Taylor & Francis wants us to shell out USD 104 for an article even if we don\u2019t know whether it is helpful for our research.  Your \u2018investment\u2019, based on abstract information only, may be a total flop.  No wonder, Sci-Hub has become the go-to source for many researchers who don\u2019t have access to a university library or a large NIH grant.<\/p>\n\n\n\n

Consider the Article Publishing Charges (APC) for a major academic journal.  At Elsevier, APCs are tiered; for the Lancet family of articles the price tag is a hefty USD 7280.  Not exactly a bargain.<\/p>\n\n\n\n

There is now some push-back to this business model from various stakeholders.  The respected Journal of Human Evolution<\/em> made waves recently [3]<\/a> when its entire editorial board resigned.  Editors felt trapped and complained about working conditions, especially the impact and intrusion of AI into their managing and review duties.  There are more cases and more editors leaving academic publishing companies every year.<\/p>\n\n\n\n

Undoubtedly, there is increased tension between the time-honored peer-review process with its emphasis on review standards and careful vetting of manuscripts, and the more business- and profit-centered approach of editing houses that pursue a cost-cutting and revenue-driven strategy.  The role assigned to AI has become a major point of contention.<\/p>\n\n\n

It should be a wake-up call for researchers to be selective where they send their next article<\/p>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

We don\u2019t want to lament too much by going over journal pricing for subscriptions and manuscript publication; suffice it to say that \u2018We the Readers\u2019 should demand quality work in return. For more info on journal pricing and consequences, here are a few references [4]<\/a>,[5]<\/a>,[6]<\/a><\/p>\n\n\n\n

A recent article by Wang et al. reflects the wonderful world we live in [7]<\/a>.  This is an article on omadacycline PK and about a better\/faster way to measure plasma levels.  That\u2019s all fine and good, but why did the authors think that \u2013 having this great new assay \u2013 there is a clinical need for therapeutic drug monitoring (TDM ) for this drug?  They did not provide details about how this assay stands to contribute to patient management, but state that \u2018TDM is a must\u2019.  Based on what?  What is the PK profile in various disease conditions and are there relevant differences that TDM can adjust for?  Is there a concern about low PK levels In ICU patients, or some so far unrecognized toxicity that needs to be avoided with TDM?  None of that is addressed in the article.<\/p>\n\n\n\n

In their analysis of 127 blood samples from 54 patients with \u2018severe pneumonia\u2019, the omadacycline plasma concentrations were lower than in normal volunteers.\u00a0 However, peak levels in these patients averaged 1181 ng\/mL, well above the breakpoint of 0.5 \u00b5g\/mL.\u00a0 There would be a better rationale for doing TDM for tigecycline and eravacycline, both drugs with high protein binding and low free drug levels.<\/p>\n\n\n\n

Nonetheless, the authors state that \u201ctherapeutic drug monitoring (TDM) of omadacycline in critically ill patients is essential\u201d   They provide six (!) references in support of  TDM for antibiotics in general but none mention tetracyclines, all are related to \u03b2-lactams.  A case of guilty by association or a hefty dose of extrapolation, it seems.<\/p>\n\n\n\n

Now the fun part.\u00a0 The article mixes up \u2018omeprazole\u2019 with ‘omadacycline\u2019, as in this sentence \u201ctrough concentration distribution of omeprazole in patients is 243.15 \u00b1 124.74 ng\/mL,\u201d.\u00a0 Here is the corresponding graph:\u00a0<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Lo and behold \u2013 some sentence parts are duplicated (\u201cThese results These results\u201d), maybe for emphasis?  In the absence of editorial cross-checking, this indicates to us that the AI bot is not infallible.<\/p>\n\n\n\n

This article did not have peer review, it seems.\u00a0 They did not even use a spell checker.\u00a0 Relevant PK literature is not quoted.\u00a0 Claims are made without supporting evidence.\u00a0 The author\u2019s suggestion to introduce TDM for omadacycline is not laid out at all.\u00a0 TDM is well established for aminoglycosides and vancomycin, less so for polymyxins.\u00a0 We are unaware of anyone seriously suggesting that TDM is required for the tetracycline class of drugs.<\/p>\n\n\n

\n

The authors propose that PK testing be done because it can be done.\u00a0 Not a good argument in our estimation.<\/p>\n<\/blockquote>\n\n\n

<\/p>\n\n\n\n

In summary, we wonder about the review process in place at Nature Portfolio Review<\/em>.<\/p>\n\n\n\n

Had the article been just about a new analytical method, we would have ignored it, assuming that it was mainly written to beef up someone\u2019s CV to support someone\u2019s academic advancement.\u00a0 Given the unsubstantiated claims about future use and the call for TDM, we feel that editors and peer reviewers should have stepped in here and redacted the manuscript.<\/p>\n\n\n\n

We live in the \u2018Brave New World\u2019 of AI. Of course, there is a place for AI in journal work, but we don’t want to see thoughtful editorial review replaced by machine algorithms entirely.\u00a0 A prestigious journal like Nature has a reputation to defend; not everything should be entrusted to the AI autopilot.<\/p>\n\n\n\n

There are a few theoretical reasons why one might consider TDM for certain tetracyclines.\u00a0 For example, tigecycline is often administered at twice its labeled dose in severe infections, like those caused by acinetobacter.\u00a0 We don\u2019t have clinical data to suggest that \u2018more is better\u2019 given the drug\u2019s paradoxical PK profile.\u00a0 While higher doses will not increase free drug AUC, it stands to increase toxicity. As many CRAB patients are critically ill, treated in the ICU for pneumonia, TDM may have a very limited role in special circumstances.<\/p>\n\n\n\n

But this is not what the Wang article is about…<\/p>\n\n\n\n

ATTACHMENT<\/strong><\/p>\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

REFERENCES
<\/strong>[1]<\/a> Journals Cost How Much?   Accessed 8\/7\/2025  https:\/\/www.library.ucsf.edu\/about\/subscriptions\/journals-costs\/
[2]<\/a> Rose-Wiles L.  Journal of Electronic Librarianship, 23,  2011: 219
[3]<\/a> Price M.  Journal editors\u2019 mass resignation marks \u2018sad day for paleoanthropology\u2019.  doi: 10.1126\/science.zsk9d10
[4]<\/a> The Hidden Costs of Pricey Journals: How Academic Paywalls Hinder Scientific Progress.  2024 https:\/\/suchscience.net\/the-hidden-costs-of-pricey-journals\/
[5]<\/a> An Y.  The Cost of Knowledge: Academic Journal Pricing and Research Dissemination, 2024. https:\/\/ssrn.com\/abstract=4691124 or http:\/\/dx.doi.org\/10.2139\/ssrn.4691124
[6]<\/a> Sanderson K  Journal editors are resigning en masse: what do these group exits achieve?  Nature 628: 244 (2024)
[7]<\/a> Wang.  LC-MS\/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application.  Nature Portfolio Scientific Reports 15: 27728, 2025<\/p>\n","protected":false},"excerpt":{"rendered":"

New medical and science journals pop up in our mailbox on a biweekly basis.  Offers to join as Editor, solicitation for articles based on past publications, invitations for subject reviews come as unsolicited emails.  Medical publication houses, old and new, are expanding, adding more and more subspecialties to their established Continue reading JOURNAL BUSINESS vs EDITORIAL OVERSIGHT<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":4908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[140,227,3,18],"tags":[198,2177,1271,176,2354,2353,2176,2360,2357,2355,1915,425,1583,2361,2352,2359,2356,433,77,2125,2358,979,263,980,43,48],"class_list":["post-4898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interesting_facts","category-recent_literature","category-the_news","category-the_viewpoint","tag-acinetobacter","tag-ai","tag-allphase-pharma-consulting","tag-aminoglycoside","tag-apc","tag-article-publishing-charge","tag-artificial-intelligence","tag-carbapenem-resistant-acinetobacter-baumannii","tag-charges-for-authors","tag-cost-of-published-articles","tag-crab","tag-eravacycline","tag-harald-reinhart","tag-high-dose-tigecycline","tag-icu-patient","tag-lack-of-editorial-quality","tag-library-purchasing","tag-omadacycline","tag-pneumonia","tag-polymyxin","tag-resignation-of-editors","tag-tdm","tag-tetracycline","tag-therapeutic-drug-monitoring","tag-tigecycline","tag-vancomycin"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/HR_BLOG-PUBLISHERS-.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1h0","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":6499,"url":"https:\/\/allphasepharma.com\/dir\/2026\/04\/10\/6499\/treating-serious-crab-infections\/","url_meta":{"origin":4898,"position":0},"title":"Treating Serious CRAB Infections","author":"Harald","date":"April 10, 2026","format":false,"excerpt":"There are MDR pathogens, and there is carbapenem-resistant A. baumannii, aka CRAB. This surely must be one of the most formidable bacterial organisms. It has resistance mechanisms second to none.\u00a0 When found in patients, it is very difficult to eradicate and extremely difficult to get rid off, once established in\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/CRAB.jpg?fit=1200%2C338&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/CRAB.jpg?fit=1200%2C338&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/CRAB.jpg?fit=1200%2C338&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/CRAB.jpg?fit=1200%2C338&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/CRAB.jpg?fit=1200%2C338&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":689,"url":"https:\/\/allphasepharma.com\/dir\/2014\/08\/04\/689\/some-thoughts-about-eravacycline-based-on-the-phase-2-ciai-study\/","url_meta":{"origin":4898,"position":1},"title":"Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study","author":"Harald","date":"August 4, 2014","format":false,"excerpt":"Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1]\u00a0 This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/eravacycline-copy.jpg?fit=481%2C212&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":3100,"url":"https:\/\/allphasepharma.com\/dir\/2017\/01\/24\/3100\/kill-mocking-bug-cre-crab-variety\/","url_meta":{"origin":4898,"position":2},"title":"To Kill A Mocking Bug – of the CRKP or CRAB Variety","author":"Harald","date":"January 24, 2017","format":false,"excerpt":"Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times \u2013 or both - to improve T>MIC for the\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1401,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/30\/1401\/a-renaissance-for-old-drugs-fosfomycin-and-colistin\/","url_meta":{"origin":4898,"position":3},"title":"A Renaissance for Old Drugs: Fosfomycin and Colistin","author":"Harald","date":"April 30, 2015","format":false,"excerpt":"Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some\u00a0time but not in the\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3330,"url":"https:\/\/allphasepharma.com\/dir\/2017\/05\/08\/3330\/connections-mimaherellia-acinetobacter-double-helix-lwoff-crab\/","url_meta":{"origin":4898,"position":4},"title":"Connections: From Mima\/Herellea to Acinetobacter to the Double Helix to Lwoff to \u2026 CRAB","author":"Harald","date":"May 8, 2017","format":false,"excerpt":"There once was a Scientific American section authored by science historian James Burke called \u2018Connections\u201d. In it James Burke, a true renaissance man, showed us how an 'internet' of serendipitous encounters, connections between persons, places and events led to advances in science. His delightful tours through history are testimony to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/05\/Acinetobacter-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/05\/Acinetobacter-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/05\/Acinetobacter-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":6294,"url":"https:\/\/allphasepharma.com\/dir\/2026\/03\/14\/6294\/where-are-the-chloramphenicol-derivatives\/","url_meta":{"origin":4898,"position":5},"title":"Where are the Chloramphenicol Derivatives?","author":"Harald","date":"March 14, 2026","format":false,"excerpt":"The 1st edition of Mandell's textbook 'Principles and Practice of Infectious Disease' was published in 1979.\u00a0 It has grown ever since in size and numbers of chapters.\u00a0 Now in its 10th edition, it is and remains an impressive publication, a 2-volume set, a comprehensive reference textbook, kept up-to-date with periodic\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/amphenicols.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/amphenicols.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/amphenicols.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=4898"}],"version-history":[{"count":12,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4898\/revisions"}],"predecessor-version":[{"id":4918,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4898\/revisions\/4918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/4908"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=4898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=4898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=4898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}